553 related articles for article (PubMed ID: 15012171)
1. Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus.
Rajagopalan R; Perez A; Ye Z; Khan M; Murray FT
Drugs Aging; 2004; 21(4):259-71. PubMed ID: 15012171
[TBL] [Abstract][Full Text] [Related]
2. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.
Rajagopalan R; Xu Y; Abbadessa M;
Am J Geriatr Pharmacother; 2006 Jun; 4(2):123-33. PubMed ID: 16860259
[TBL] [Abstract][Full Text] [Related]
3. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Roberts VL; Stewart J; Issa M; Lake B; Melis R
Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial.
Kaku K
Curr Med Res Opin; 2009 May; 25(5):1111-9. PubMed ID: 19309251
[TBL] [Abstract][Full Text] [Related]
5. Earlier triple therapy with pioglitazone in patients with type 2 diabetes.
Charpentier G; Halimi S;
Diabetes Obes Metab; 2009 Sep; 11(9):844-54. PubMed ID: 19614944
[TBL] [Abstract][Full Text] [Related]
6. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
Charbonnel B; Schernthaner G; Brunetti P; Matthews DR; Urquhart R; Tan MH; Hanefeld M
Diabetologia; 2005 Jun; 48(6):1093-104. PubMed ID: 15889234
[TBL] [Abstract][Full Text] [Related]
8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
[TBL] [Abstract][Full Text] [Related]
10. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.
Bolli G; Dotta F; Colin L; Minic B; Goodman M
Diabetes Obes Metab; 2009 Jun; 11(6):589-95. PubMed ID: 19515179
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
[TBL] [Abstract][Full Text] [Related]
12. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
[TBL] [Abstract][Full Text] [Related]
13. Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.
Lewin A; Lipetz R; Wu J; Schwartz S
Clin Ther; 2007 May; 29(5):844-855. PubMed ID: 17697903
[TBL] [Abstract][Full Text] [Related]
14. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
16. Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18).
Scheen AJ; Tan MH; Betteridge DJ; Birkeland K; Schmitz O; Charbonnel B;
Diabet Med; 2009 Dec; 26(12):1242-9. PubMed ID: 20002476
[TBL] [Abstract][Full Text] [Related]
17. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
Garber AJ; Schweizer A; Baron MA; Rochotte E; Dejager S
Diabetes Obes Metab; 2007 Mar; 9(2):166-74. PubMed ID: 17300592
[TBL] [Abstract][Full Text] [Related]
18. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy.
Berhanu P; Perez A; Yu S
Diabetes Obes Metab; 2007 Jul; 9(4):512-20. PubMed ID: 17587394
[TBL] [Abstract][Full Text] [Related]
19. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.
Davidson JA; McMorn SO; Waterhouse BR; Cobitz AR
Clin Ther; 2007 Sep; 29(9):1900-14. PubMed ID: 18035190
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Pratley RE; Reusch JE; Fleck PR; Wilson CA; Mekki Q;
Curr Med Res Opin; 2009 Oct; 25(10):2361-71. PubMed ID: 19650752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
